<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amiodarone dosing in adults by indication</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amiodarone dosing in adults by indication</h1>
<div class="graphic"><div class="figure"><div class="ttl">Amiodarone dosing in adults by indication</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Indications</td> <td class="subtitle1">Loading dose</td> <td class="subtitle1">Maintenance dose</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Atrial arrhythmias</td> </tr> <tr> <td class="indent1"> <ul> <li>Prevention of recurrent PAF</li> <li>Pharmacologic cardioversion of PAF</li> </ul> </td> <td> <ul> <li>Total loading dose: 6 to 10 grams</li> <li>Outpatient: Given as 400 to 600 mg orally per day in divided doses with meals</li> <li>Inpatient: Given as 400 to 1200 mg orally per day in divided doses with meals</li> </ul> </td> <td> <ul> <li>Lowest effective dose, usually 100 to 200 mg orally once per day</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Pretreatment before elective cardioversion or catheter ablation of AF</li> </ul> </td> <td> <ul> <li>Total loading dose: 6 to 10 grams orally over 2 to 6 weeks</li> <li>Given as 400 to 1200 mg orally per day in divided doses</li> </ul> </td> <td> <ul> <li>Lowest effective dose, usually 100 to 200 mg orally once per day</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Restoration and maintenance of NSR in critically ill patients with AF</li> <li>Ventricular rate control in critically ill patients with AF and rapid ventricular response</li> </ul> </td> <td> <ul> <li>Total IV loading dose: 1050 mg</li> <li>Given as 150 mg IV bolus over 10 to 30 minutes, followed by continuous IV infusion at 1 mg per minute for 6 hours, then 0.5 mg per minute for 18 hours*</li> <li>IV infusion (0.5 mg per minute) may need to be extended past 24 hours if unable to transition to oral therapy</li> <li>If amiodarone will be used chronically: Following IV infusion, give 400 to 1200 mg orally per day in divided doses to complete a total (IV plus oral) loading dose of 10 grams; consider overlapping IV and oral amiodarone for 24 to 48 hours</li> </ul> </td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Ventricular arrhythmias</td> </tr> <tr> <td class="indent1"> <ul> <li>Primary and secondary prevention of SCD in patients with LV dysfunction who are not candidates for or refuse ICD implantation</li> </ul> </td> <td> <ul> <li>Total oral loading dose: 6 to 10 grams</li> <li>Outpatient: 400 to 600 mg orally per day in divided doses with meal</li> <li>Inpatient: 400 to 1200 mg orally per day in divided doses with meals for 1 to 2 weeks</li> </ul> </td> <td> <ul> <li>Lowest effective dose</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Prevention of ventricular arrhythmias in patients with ICDs to decrease risk of shocks</li> </ul> </td> <td> <ul> <li>Total loading dose: 6 to 10 grams</li> <li>Outpatient: Given as 400 to 600 mg orally per day in divided doses with meals</li> <li>Inpatient: Given as 400 to 1200 mg orally per day in divided doses with meals until desired dose is achieved</li> </ul> </td> <td> <ul> <li>Lowest effective dose</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Cardiac arrest associated with VF or pulseless VT</li> </ul> </td> <td> <ul> <li>300 mg IV or IO rapid bolus with a repeat dose of 150 mg as indicated</li> <li>Upon return of spontaneous circulation follow with an infusion of 1 mg per minute for 6 hours and then 0.5 mg per minute for 18 hours*</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Electrical (VT) storm and incessant VT in hemodynamically stable patients</li> </ul> </td> <td> <ul> <li>Total IV loading dose: 1050 mg</li> <li>150 mg IV bolus over 10 minutes, followed by continuous IV infusion at 1 mg per minute for 6 hours, then 0.5 mg per minute for 18 hours</li> <li>IV infusion (0.5 mg per minute) may need to be extended past 24 hours if unable to transition to oral therapy<sup>¶</sup></li> <li>Additional 150 mg boluses may be given if VT storm recurs</li> <li>If amiodarone will be used chronically: Following IV infusion 400 to 1200 mg orally per day in divided doses to complete a total (IV plus oral) loading dose of 10 grams. Consider overlapping IV and oral amiodarone for 24-48 hours</li> </ul> </td> <td> <ul> <li>If amiodarone is used chronically: Lowest effective dose</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>PAF: paroxysmal atrial fibrillation; AF: atrial fibrillation; NSR: normal sinus rhythm; IV: intravenous; SCD: sudden cardiac death; LV: left ventricular; ICD: implantable cardioverter-defibrillator; VF: ventricular fibrillation; VT: ventricular tachycardia; IO: intraosseous.</p>
<p>* When administered to critically ill patients with atrial fibrillation and rapid ventricular response, repeated 150 mg boluses can be given over 10 to 30 minutes if needed, but no more than six to eight additional boluses should be administered in any 24-hour period.</p>
    
    ¶ Typically, patients are given 1 or 2 doses of oral amiodarone prior to discontinuation of the IV infusion.</div><div id="graphicVersion">Graphic 117524 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
